NeOnc Technologies Holdings, Inc.
$5.17
▼
-2.3%
2026-04-21 08:29:01
www.neonc.com
NGM: NTHI
Explore NeOnc Technologies Holdings, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$133.03 M
Current Price
$5.17
52W High / Low
$12.99 / $3.2
Stock P/E
—
Book Value
$-0.81
Dividend Yield
—
ROCE
129%
ROE
122.08%
Face Value
—
EPS
$-3.2
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
5
Beta
—
Debt / Equity
-0
Current Ratio
0.07
Quick Ratio
0.07
Forward P/E
-3.68
Price / Sales
3,333.88
Enterprise Value
$135.76 M
EV / EBITDA
—
EV / Revenue
3,394.87
Rating
None
Target Price
—
EPS Forecast (FY)
—
Pros
- Healthy return on equity.
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Valuation is not stretched on P/E basis.
Cons
- Current ratio suggests tighter short-term liquidity.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Halozyme Therapeutics, Inc. | $68.8 | 26.89 | $8.18 B | — | 34.18% | 1.54% | $82.22 / $47.5 | $0.41 |
| 2. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 3. | Corcept Therapeutics Incorporated | $46.34 | 49.18 | $4.9 B | — | 6.68% | 15.02% | $91 / $28.66 | $6.11 |
| 4. | Ascentage Pharma Group Internat | $25.65 | — | $18.58 B | — | -25.48% | -1.55% | $95.35 / $36.5 | $0.52 |
| 5. | Arbutus Biopharma Corporation | $4.6 | — | $899.2 M | — | -30.53% | -38.52% | $5.1 / $2.94 | $0.4 |
| 6. | Orchestra BioMed Holdings, Inc. | $4.35 | — | $268.03 M | — | -52.8% | -1.09% | $5.42 / $2.2 | $0.94 |
| 7. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0.04 M | 0.02 M | — |
| Operating Profit | -13.63 M | -6.93 M | -5.71 M | -37.58 M | -2.1 M | — |
| Net Profit | -15.52 M | -8.62 M | -5.68 M | -38 M | -2.25 M | — |
| EPS in Rs | -0.65 | -0.36 | -0.24 | -1.6 | -0.09 | -0.12 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0.04 M | 0.08 M | 0.07 M | 0.02 M |
| Operating Profit | -58.17 M | -7.14 M | -8.1 M | -2.84 M |
| Net Profit | -62.15 M | -11.9 M | -14.92 M | -3.05 M |
| EPS in Rs | -2.61 | -0.5 | -0.63 | -0.13 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 2.82 M | 3.42 M | 1.27 M | 0.73 M |
| Total Liabilities | 20.33 M | 8.92 M | 15.25 M | 2.3 M |
| Equity | -17.51 M | -5.5 M | -13.99 M | -1.58 M |
| Current Assets | 1.39 M | 2.2 M | 1.27 M | 0.73 M |
| Current Liabilities | 20.04 M | 8.92 M | 15.25 M | 2.3 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -20.36 M | -4.21 M | -1.88 M | -0.88 M |
| Investing CF | -0.5 M | 0 M | — | — |
| Financing CF | 20.86 M | 4.25 M | 1.28 M | 1.49 M |
| Free CF | -20.86 M | -4.21 M | -1.88 M | -0.88 M |
| Capex | -0.5 M | — | — | — |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 17.79% | 252.31% | — | — |
| Earnings Growth % | 20.26% | -389.74% | — | — |
| Profit Margin % | -14335.5% | -21176.05% | -15233.78% | — |
| Operating Margin % | -8605.45% | -11492.25% | -14188.02% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -10958.39% | -17310.99% | -14233.02% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.